| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1192d5c6fb70a6cef789e3f9f9743514 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y306-05002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-84 |
| filingDate |
2021-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_327533111f0b3b6c4fcbcc00ad285b35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f928d582e9fb194c60d12692accc332e |
| publicationDate |
2022-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022112205-A1 |
| titleOfInvention |
Heteroaryl Modulators of RAS GTPase |
| abstract |
RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds. |
| priorityDate |
2020-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |